CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR- mutant non-small cell lung cancer (NSCLC), primary analysis of the phase III NeoADAURA trial showed.

Among more than 350 patients with stage II-IIIB disease, rates of MPR reached 26% with osimertinib and chemotherapy combined and 25% with single-agent osimertinib, as compared with 2% in the control group treated with chemotherapy alone ( P <0.0001 for both comparisons), reported Jamie Chaft, MD, of Memorial Sloan Kettering Cancer Center in New York City, at the American Society of Clinical Oncology (ASCO) annual meeting .

"I hope in the next 12 minutes I can relay enough of this study data to co

See Full Page